Related Experiment Video
Updated: Jan 21, 2026

Activating Autophagy by Aerobic Exercise in Mice
Published on: February 3, 2017
mTOR hyperactivation in Down Syndrome underlies deficits in autophagy induction, autophagosome formation, and
Matteo Bordi1,2,3, Sandipkumar Darji4, Yutaka Sato4
1Center for Dementia Research, Nathan Kline Institute, Orangeburg, NY, USA. matteobordi@gmail.com.
Abstract:
Down syndrome (DS), a complex genetic disorder caused by chromosome 21 trisomy, is associated with mitochondrial dysfunction leading to the accumulation of damaged mitochondria. Here we report that mitophagy, a form of selective autophagy activated to clear damaged mitochondria is deficient in primary human fibroblasts derived from individuals with DS leading to accumulation of damaged mitochondria with consequent increases in oxidative stress. We identified two molecular bases for this mitophagy deficiency: PINK1/PARKIN impairment and abnormal suppression of macroautophagy. First, strongly downregulated PARKIN and the mitophagic adaptor protein SQSTM1/p62 delays PINK1 activation to impair mitophagy induction after mitochondrial depolarization by CCCP or antimycin A plus oligomycin. Secondly, mTOR is strongly hyper-activated, which globally suppresses macroautophagy induction and the transcriptional expression of proteins critical for autophagosome formation such as ATG7, ATG3 and FOXO1. Notably, inhibition of mTOR complex 1 (mTORC1) and complex 2 (mTORC2) using AZD8055 (AZD) restores autophagy flux, PARKIN/PINK initiation of mitophagy, and the clearance of damaged mitochondria by mitophagy. These results recommend mTORC1-mTORC2 inhibition as a promising candidate therapeutic strategy for Down Syndrome.
Insights
Down syndrome (DS) involves mitochondrial damage due to deficient mitophagy. Inhibiting mTORC1/mTORC2 restores mitophagy, clearing damaged mitochondria and reducing oxidative stress, offering a potential therapy for DS.
Area of Science:
- Cell Biology
- Genetics
- Biochemistry
Background:
- Down syndrome (DS) is linked to mitochondrial dysfunction and damaged mitochondria accumulation.
- Mitophagy, crucial for clearing damaged mitochondria, is impaired in DS.
Purpose of the Study:
- To investigate the molecular mechanisms behind mitophagy deficiency in Down syndrome.
- To explore potential therapeutic strategies targeting mitophagy in DS.
Main Methods:
- Primary human fibroblasts from individuals with DS were analyzed.
- Investigated PINK1/PARKIN pathway and macroautophagy regulation by mTOR.
- Utilized AZD8055 to inhibit mTORC1/mTORC2.
Main Results:
- DS fibroblasts exhibit impaired mitophagy and increased oxidative stress.
- Downregulated PARKIN and p62, and hyperactivated mTOR were identified as key factors.
- mTORC1/mTORC2 inhibition by AZD8055 restored mitophagy and cleared damaged mitochondria.
Conclusions:
- Mitophagy deficiency in DS stems from PINK1/PARKIN impairment and mTOR-driven macroautophagy suppression.
- Targeting mTORC1/mTORC2 with inhibitors like AZD8055 shows therapeutic promise for Down syndrome by restoring mitochondrial quality control.
Related Concept Videos
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Autophagy
An autophagic pathway consists of a series of signaling events activated in response to diverse stress and physiological conditions such as food deprivation,...
PI3K/mTOR/AKT Signaling Pathway
Attention-Deficit/Hyperactivity Disorder
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
Induction
A...
Formation of Species

